Guest Column: Labeling, Packaging Front-And-Center As Unique Device Identifiers Move Forward, Survey Shows
This article was originally published in The Gray Sheet
In this Gray Sheet guest column, Prism ID’s Kevin Grygiel ticks off survey responses from the device industry that shows that manufacturers are generally OK with UDI implementation, but still have trouble with some of the details. Further, the firm’s survey shows that one-third of respondents don’t believe they are ready for FDA inspections involving review of UDI activities and materials.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.